EDGAR Filing Documents for 0001640334-17-002579

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:

SEC Accession No. 0001640334-17-002579

Filing Date

2017-12-04

Accepted

2017-12-01 19:04:49

Documents

Period of Report

2017-12-01

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 6-K	nymox_6k.htm	6-K	6241
2	NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS	nymox_ex991.htm	EX-99.1	148147
3	FORM OF PROXY	nymox_ex992.htm	EX-99.2	1390
4		nymox_ex992img1.jpg	GRAPHIC	117322
5		nymox_ex992img2.jpg	GRAPHIC	83273
6		nymox_ex991img1.jpg	GRAPHIC	631
	Complete submission text file	0001640334-17-002579.txt		434293

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 171235243
SIC: 2835 In Vitro & In Vivo Diagnostic Substances